ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,692.52
0.14%
Dow Jones
41,520.98
-0.77%
Gold vs US Dollar
3,031.96
1.04%
Brent Oil
70.56
-0.14%
Bitcoin
81,598.09
-2.93%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Inventiva Sa (0RNK) Share Price

0RNK Inventiva Sa

7.62
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Inventiva Sa LSE:0RNK London Stock Exchange Ordinary Share FR0013233012 INVENTIVA ORD SHS
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.00 0.00 7.62 0.00 0.00 0.00 0.00  47 00:00:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Biological Pds,ex Diagnstics 23.16M -110.43M -2.1189 -1.30 397.12M
 Type  Size  Price  Time  Units 
  3 2.82 11:37:26 EUR
 
Recent News
DateTimeSource
HeadlineMore 0RNK News
26/02/202521:00UKREGInventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
26/02/202521:00UKREGInventiva annonce la publication dans Biomedicine & Pharmacotherapy des résultats d'une étude préclinique montrant une amélioration de l'hypertension portale avec le traitement par lanifibranor
20/02/202521:00UKREGInventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
20/02/202521:00UKREGInventiva et Hepalys Pharma, Inc. annoncent le lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du premier participant dans l'étude de Phase 1
10/02/202521:00UKREGInventiva publie ses résultats financiers préliminaires pour l'exercice fiscal 2024¹ et fait le point sur son activité
10/02/202521:00UKREGInventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
29/01/202521:00UKREGInventiva annonce la publication dans la revue « Journal of Hepatology » des résultats de l’étude clinique de preuve de concept initiée par un investigateur évaluant lanifibranor chez des patients atteints de DT2 et MASLD
Period
Draw mode
Technical Analysis for Inventiva Sa
Get quick technical analysis for Inventiva Sa.
Price Indicators
Evaluate in real-time the trend for this stock with base on twelve different studies.
Candlesticks
Verify the trend for the closing and opening times for this stock or defined reversal patterns.
Support & Resistance
Automatically plot the main lines for support and resistance for this tock highlighting the main levels.


Loading Follow Feed...

Your Recent History

LSE
0RNK
Inventiva
ASX
JBY
James Bay Minerals
TG
ASMF
ASML Holding NV
LSE
0VGE
Ssr Mining
ASX
CTD
Corporate Travel Managem...
LSE
NFDS
Northern Foods
AMEX
GK
Advisorshares Gerber Kaw...
TG
SOU
Singapore Exchange
ASX
ABR
American Pacific Borates
TSX
MOZ
Marathon Gold
NASDAQ
ACST
Acasti Pharma
EU
IPS
Ipsos
NYSE
ACV
Virtus Diversified Incom...
EU
ITP
Interparfums
LSE
0EHG
Forestiere Equatoriale
NYSE
EVF
Eaton Vance Senior Income
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads